Zobrazeno 1 - 10
of 220
pro vyhledávání: '"Kanthou, C"'
Publikováno v:
In Experimental and Molecular Pathology June 2015 98(3):532-539
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Holmes, T., Brown, A.W., Suggitt, M., Shaw, L.A., Simpson, L., Harrity, J.P.A., Tozer, G.M., Kanthou, C.
Combretastatin A-4 phosphate (CA4P) is a microtubule-disrupting tumour-selective vascular disrupting agent (VDA). CA4P activates the actin-regulating RhoA-GTPase/ ROCK pathway, which is required for full vascular disruption. While hypoxia renders tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::db6c4876378487ee1807e0bf488b8e83
https://eprints.whiterose.ac.uk/162676/1/s41598-020-66568-8.pdf
https://eprints.whiterose.ac.uk/162676/1/s41598-020-66568-8.pdf
The combretastatins have attracted significant interest as small molecule therapies for cancer due to their ability to function as vascular disrupting agents. We have successfully prepared a range of combretastatin analogs that are based on a novel s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::13fe98ae0052cc258ce4e71c9aa4be66
Autor:
English, W.R., Lunt, S.J., Fisher, M., Lefley, D.V., Dhingra, M., Lee, Y-C., Bingham, K., Hurrell, J.E., Lyons, S.K., Kanthou, C., Tozer, G.M.
Elevated plasma concentrations of soluble VEGFA isoforms are associated with poor prognosis in parallel with improved response to treatment with the anti-VEGFA antibody bevacizumab. To uncover the underlying mechanism to these observations, we admini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::ed128186a8c643142049a645d4625217
This work describes the topological analysis of the vasculature of tumours. The analysis is performed with a scale-space technique, which traces the centrelines of vessels as topological ridges of the image intensities and then obtains a series of me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::af1a8cd6e51c427a108523d700d62a8a
https://openaccess.city.ac.uk/id/eprint/17944/1/Vasculature_Ang1Ang2WTB.pdf
https://openaccess.city.ac.uk/id/eprint/17944/1/Vasculature_Ang1Ang2WTB.pdf
Autor:
Williams, L. J., Mukherjee, D., Fisher, M., Reyes-Aldasoro, C. C., Akerman, S., Kanthou, C., Tozer, G. M.
Publikováno v:
British Journal of Pharmacology
Background and Purpose\ud \ud Combretastatin A-4 3-O-phosphate (CA4P) is in clinical trial as a tumour vascular disrupting agent (VDA) but the cause of blood flow disruption is unclear. We tested the hypothesis that activation of Rho/Rho kinase (ROCK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::2ee316c82b41a87d4ab72af0c485f3fe
http://europepmc.org/articles/PMC4294113
http://europepmc.org/articles/PMC4294113
The combretastatins are an important class of tubulin-binding agents. Of this family, a number of compounds are potent tumor Vascular Disrupting Agents (VDAs) and have shown promise in the clinic for cancer therapy. We have developed a modular synthe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::07fa5e0ff8b71cba2c587bc6f613ba55
Autor:
Akerman, S, Fisher, M, Daniel, RA, Lefley, D, Reyes-Aldasoro, CC, Lunt, SJ, Harris, S, Bjorndahl, M, Williams, LJ, Evans, H, Barber, PR, Prise, VE, Vojnovic, B, Kanthou, C, Tozer, GM
Antiangiogenic therapy based on blocking the actions of vascular endothelial growth factor-A (VEGF) can lead to "normalization" of blood vessels in both animal and human tumors. Differential expression of VEGF isoforms affects tumor vascular maturity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::254e7a91ed1accbe34e86a55ef15ca94
https://ora.ox.ac.uk/objects/uuid:bf69cf26-c8fb-4249-bf4d-f59281942eb4
https://ora.ox.ac.uk/objects/uuid:bf69cf26-c8fb-4249-bf4d-f59281942eb4
Background: Vascular endothelial growth factor-A (VEGF) is produced by most cancer cells as multiple alternatively spliced isoforms, which display distinct receptor and matrix binding characteristics. In addition to being a major inducer of tumour an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::eb0569d7822bbfa0887599bfa71651af